Dr. Lin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
- University of Texas M D Anderson Cancer CenterFellowship, Hematopathology, 1999 - 2000
- Yale-New Haven Medical CenterResidency, Pathology-Anatomic and Clinical, 1995 - 1999
- Nanjing Medical UniversityClass of 1982
Certifications & Licensure
- CA State Medical License 2014 - 2026
- TX State Medical License 2003 - 2025
- MI State Medical License 1999 - 2006
- AR State Medical License 2000 - 2002
- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Hematology
Publications & Presentations
PubMed
- From the archives of MD Anderson Cancer Center: Composite mantle cell lymphoma and lymphoplasmacytic lymphoma involving bone marrow at presentation.Yiannis Petros Dimopoulos, Beenu Thakral, Pei Lin, Gokce Toruner, Zhuang Zuo
Annals of Diagnostic Pathology. 2024-12-01 - The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome.Yiannis Petros Dimopoulos, Wei Wang, Sa A Wang, Sanam Loghavi, Courtney D DiNardo
American Journal of Hematology. 2024-12-01 - CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis.Sunil Acharya, Rafet Basar, May Daher, Hind Rafei, Ping Li
Cancer Discovery. 2024-10-04
Journal Articles
- Original Contribution Utility of JAK2 V617F Allelic Burden in Distinguishing Chronic Myelomonocytic Leukemia from Primary Myelofibrosis with Monocytosis☆Shaoying Li, L Jeffrey Medeiros, Pei Lin, Srdan Verstovsek, ScienceDirect
- Original Contribution IgM Plasma Cell Myeloma in the Era of Novel Therapy: A Clinicopathologic Study of 17 Cases☆Shaoying Li, Pei Lin, L Jeffrey Medeiros, Guilin Tang, ScienceDirect
Abstracts/Posters
- A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)Pei Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)Pei Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
- Parkinsons Disease Linked with Most Cancers in TaiwanJune 19th, 2015
- Parkinson’s Disease Linked with Most Cancers in TaiwanJune 19th, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: